ITMCTR2100005161
Not Yet Recruiting
Phase 1
Clinical Efficacy Evaluation and Mechanism Study of Anti-Hepatic Fibrosis Effectively Treated Prescription by Supplementing Deficiency and Clearing Collaterals
Chengdu University of Traditional Chinese Medicine0 sitesTBD
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Chengdu University of Traditional Chinese Medicine
- Status
- Not Yet Recruiting
- Last Updated
- 3 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. Meet the diagnostic criteria for chronic hepatitis B fibrosis;
- •2\. Diagnostic criteria of TCM syndrome of Qi deficiency and collateral obstruction;
- •3\. Aged between 18\-65 years old;
- •4\. Good compliance and signed informed consent.
Exclusion Criteria
- •1\. Those with poor compliance;
- •2\. Those who are participating in other scientific research projects;
- •3\. Diagnosed as severe chronic hepatitis B or prone to severe hepatitis;
- •4\. Alcoholic, drug\-related, infectious, hereditary, immune, and other viral liver diseases;
- •5\. Decompensated patients after hepatitis;
- •6\. Patients with severe heart, brain, lung and kidney diseases or tumors;
- •7\. Pregnant women or lactating women; mentally ill or unable to cooperate.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Not Yet Recruiting
Phase 1
Study for clinical efficacy evaluation and mechanism of Chinese medicine in relieving antibiotic resistance and sensitizing resistant bacteria by taking drug-resistant bacterial diarrhea as an exampleDrug-resistant bacterial diarrhea in childrenITMCTR1900002803Affiliated Hospital of Changchun University of Traditional Chinese Medicine
Not Yet Recruiting
Phase 1
Investigating the clinical efficacy and mechanism of Runfei Huayu recipe in treating connective tissue disease merger interstitial lung disease based on Th17/Treg glycolytic pathwayITMCTR2200006523Taizhou Hospital of traditional Chinese Medicine
Completed
N/A
Clinical Research on the efficacy evaluation and the biomarker of nivolumab to an advance malignant melanomamalignant melanomaJPRN-UMIN000016608Public Health Research Foundation128
Active, Not Recruiting
N/A
A study to investigate belimumab for the treatment of chronic immune thrombocytopeniaChronic Immune ThrombocytopeniaMedDRA version: 15.1Level: LLTClassification code 10051057Term: Idiopathic thrombocytopeniaSystem Organ Class: 100000004851Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]EUCTR2011-000241-21-DEGlaxoSmithKline Research & Development Limited40
Active, Not Recruiting
N/A
A study to investigate belimumab for the treatment of chronic immune thrombocytopeniaChronic Immune ThrombocytopeniaMedDRA version: 14.1Level: LLTClassification code 10051057Term: Idiopathic thrombocytopeniaSystem Organ Class: 10005329 - Blood and lymphatic system disordersTherapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]EUCTR2011-000241-21-GBGlaxoSmithKline Research & Development Limited40